The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling
- PMID: 11376112
- DOI: 10.1210/mend.15.6.0645
The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling
Abstract
Müllerian inhibiting substance (MIS or anti-Müllerian hormone) is a member of the transforming growth factor-beta family and plays a pivotal role in proper male sexual differentiation. Members of this family signal by the assembly of two related serine/threonine kinase receptors, referred to as type I or type II receptors, and downstream cytoplasmic Smad effector proteins. Although the MIS type II receptor (MISRII) has been identified, the identity of the type I receptor is unclear. Here we report that MIS activates a bone morphogenetic protein-like signaling pathway, which is solely dependent on the presence of the MISRII and bioactive MIS ligand. Among the multiple type I candidates tested, only ALK2 resulted in significant enhancement of the MIS signaling response. Furthermore, dominant-negative and antisense strategies showed that ALK2 is essential for MIS-induced signaling in two independent assays, the cellular Tlx-2 reporter gene assay and the Müllerian duct regression organ culture assay. In contrast, ALK6, the other candidate MIS type I receptor, was not required. Expression analyses revealed that ALK2 is present in all MIS target tissues including the mesenchyme surrounding the epithelial Müllerian duct. Collectively, we conclude that MIS employs a bone morphogenetic protein-like signaling pathway and uses ALK2 as its type I receptor. The use of this ubiquitously expressed type I receptor underscores the role of the MIS ligand and the MIS type II receptor in establishing the specificity of the MIS signaling cascade.
Similar articles
-
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.Development. 2006 Jun;133(12):2359-69. doi: 10.1242/dev.02383. Epub 2006 May 10. Development. 2006. PMID: 16687449
-
AMH signaling: from receptor to target gene.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):65-73. doi: 10.1016/j.mce.2003.09.012. Mol Cell Endocrinol. 2003. PMID: 14656478 Review.
-
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. doi: 10.1016/j.mce.2003.09.009. Mol Cell Endocrinol. 2003. PMID: 14656474 Review.
-
Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.Mol Endocrinol. 2001 Jun;15(6):946-59. doi: 10.1210/mend.15.6.0664. Mol Endocrinol. 2001. PMID: 11376113
-
Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.J Biol Chem. 2000 Sep 8;275(36):27973-8. doi: 10.1074/jbc.M002704200. J Biol Chem. 2000. PMID: 10854429
Cited by
-
Mini review: Asymmetric Müllerian duct development in the chicken embryo.Front Cell Dev Biol. 2024 Feb 5;12:1347711. doi: 10.3389/fcell.2024.1347711. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38380340 Free PMC article. Review.
-
Characterization of the molecular mechanisms that govern anti-Müllerian hormone synthesis and activity.FASEB J. 2024 Jan;38(1):e23377. doi: 10.1096/fj.202301335RR. FASEB J. 2024. PMID: 38133902 Free PMC article.
-
A transgenic bacterial artificial chromosome approach to identify regulatory regions that direct Amhr2 and Osterix expression in Müllerian duct mesenchyme.Front Cell Dev Biol. 2022 Oct 12;10:1006087. doi: 10.3389/fcell.2022.1006087. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36313563 Free PMC article.
-
Molecular Mechanisms of AMH Signaling.Front Endocrinol (Lausanne). 2022 Jun 22;13:927824. doi: 10.3389/fendo.2022.927824. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35813657 Free PMC article. Review.
-
Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression.Front Endocrinol (Lausanne). 2022 Jun 2;13:905324. doi: 10.3389/fendo.2022.905324. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35721723 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases